Argenx Bounds Off 200-Day Line On 'Best-Case Scenario' For Blockbuster Drug

byiShook Opinion
Apr 11, 2025 - 10:50

Share

Argenx stock jumped Friday after the FDA cleared its autoimmune disease drug, Vyvgart Hytrulo, for at-home treatment. The post Argenx Bounds Off 200-Day Line On 'Best-Case Scenario' For Blockbuster Drug appeared first on Investor's Business Daily.

Argenx stock jumped Friday after the FDA cleared its autoimmune disease drug, Vyvgart Hytrulo, for at-home treatment.

The post Argenx Bounds Off 200-Day Line On 'Best-Case Scenario' For Blockbuster Drug appeared first on Investor's Business Daily.